FUJIFILM Biotechnologies Celebrates the Opening of its New Quality Control Laboratory in Denmark

HILLERØD, Denmark, April 15, 2026 – FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today held a ribbon‑cutting ceremony to mark the opening of its new, 2,000‑square‑meter (m²) quality control (QC) laboratory at its Hillerød, Denmark, commercial‑scale manufacturing site. The expanded QC footprint will enable bioassay and virology operations to meet current and future customer demand and support the site’s planned expansion.

 

Designed for flexibility and future growth, the laboratory features modern ventilation systems, personnel and material airlocks, and an open‑plan layout. The space supports approximately 100 quality team members to conduct viral safety testing for drug substance/product release, scale capacity for complex cell‑based potency and ELISA methods, and perform raw material and critical total organic carbon cleanability studies to accelerate future partner campaigns. The QC laboratory also incorporates robotics and an ongoing LIMS implementation across the company’s global network of sites to enable digital harmonization and data integrity.

 

The ribbon‑cutting ceremony was attended by FUJIFILM Biotechnologies leadership and employees, as well as Mikio Mori, Ambassador of Japan to Denmark, Hillerød Municipality Mayor Christoffer Lorenzen, and Thomas Senderovitz, M.D., The Danish Association of the Pharmaceutical Industry (Lif).

 

FUJIFILM Biotechnologies doubled its Hillerød capacity in 2024 from 6 to 12 x 20,000 L mammalian cell culture bioreactors, increasing the complexity and volume for QC testing. The expanded production scale required expanded QC capabilities and advanced analytical equipment to support current operations and anticipated future demand. The QC lab is housed within a new 7,600 m² building that also features enhanced employee amenities, office and collaboration space, utility services, and an emergency generator to ensure uninterrupted operations and timely delivery of critical test results.

 

Construction of the laboratory was completed in March 2026 and subsequently received approval from the Danish Medicines Agency (DKMA) following an on‑site inspection. Laboratory operations will begin in May 2026.

 

The new Hillerød QC laboratory is part of FUJIFILM Biotechnologies’ kojoX modular, connected network of manufacturing facilities, where harmonized equipment, layouts, methods, and digital systems are used to enable cross‑site workflows and consistent application of quality standards across regions.

 

Supporting Quotes

 

“With the expansion of our Hillerød site in late 2024, the site doubled its size from 6 bioreactors to 12 x 20,000 L bioreactors. With the expansion, the complexity and types of QC testing increased significantly. Today, we are opening a world-class GMP-approved QC laboratory to elevate our quality control and be ready for the upcoming expansion, thereby continuing to manufacture advanced biological treatments for patients with severe diseases, such as cancer and rare autoimmune diseases. Together, we’re making a measurable impact for patients and partners around the world.” – Christian Houborg, Senior Vice President, and Hillerød Site Head, FUJIFILM Biotechnologies.

 

“I have been following the evolution of FUJIFILM Biotechnologies from the early start to today as a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. FUJIFILM Holdings Corporation, headquartered in Tokyo, is a strong brand in Japan and is best known for its imaging business segment. It’s been astonishing to watch FUJIFILM Holdings Corporation over the last decade, with its strategic investments in biomanufacturing, and to see how FUJIFILM Biotechnologies, as a subsidiary, is becoming a global network with major facilities in the United States, the United Kingdom, Japan, and Denmark. It’s a great honor to be part of the opening today of a world-class quality control laboratory in Hillerød, Denmark.” – Mikio Mori, Ambassador of Japan to Denmark.

 

“As the Mayor of Hillerød, it makes me proud to open a world-class quality control laboratory in Hillerød today. Over the last decade, the city of Hillerød has evolved into a true hub for biomanufacturing. Not only does it make me proud to know that patients with severe diseases such as cancer are being treated with advanced biological therapies manufactured in Hillerød, but it also makes me proud that we can attract talent to Hillerød to ensure a facility that needs 24-hour attention. FUJIFILM Biotechnologies currently has more than 70 nationalities working in Hillerød, which contributes to the culture in Hillerød and makes it attractive for talented young people to live in Hillerød.” – Christoffer Lorenzen, Mayor of Hillerød (Denmark).

 

“It’s a true pleasure to be part of the opening of a new quality laboratory for FUJIFILM Biotechnologies in Hillerød, Denmark. Denmark is a proud life science nation, home to both young biotech upstarts and world-leading pharmaceutical companies, as well as advanced-therapy manufacturing sites. FUJIFILM Biotechnologies has benefited from this life science ecosystem when attracting talent to their manufacturing site for biological treatments in Hillerød. It’s of pivotal importance for the Danish and European life science ecosystems that we continue to invest in research and innovation, and that we ensure the right incentives to be able to maintain and attract biomanufacturing in Europe.” – Thomas Senderovitz, CEO, The Danish Association of the Pharmaceutical Industry (Lif).

 

“Our new Hillerød QC laboratory was designed with our people and our patients in mind. The open‑plan layout, advanced ventilation, and dedicated personnel and material airlocks create a comfortable and flexible workspace for our approximately 100 quality colleagues. Our team members will also have access to state‑of‑the‑art technology and equipment to support bioassay and virology operations. By pairing better working conditions with cutting‑edge technology, we’re setting a new benchmark for quality while giving our teams the tools they need to deliver for our partners.” – Christian Bechmann, Head of Quality Control, FUJIFILM Biotechnologies (Denmark)